Compare Fortinet Inc (FTNT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fortinet Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Fortinet Inc trades at $191.03 (market cap $138.75B), while State Street SPDR S&P Biotech ETF trades at $149.93 (market cap $10.11B). The key difference: Fortinet Inc is far larger — about 13.7× State Street SPDR S&P Biotech ETF's market cap, and Fortinet Inc is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fortinet Inc for 72 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| FTNT | XBI | |
|---|---|---|
Market Cap | $138.75B | $10.11B |
Volume | 2,956,908 | 12,903,266 |
Sector | Technology | Broad Market / Factor |
52-Week High | $191.27 | $169.55 |
52-Week Low | $75.23 | $104.99 |
Typical Hold Time | 72 Days | 37 Days |
Enterprise Value | $135.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FTNT trades at $189.28, down 1.04% on the day but near its 52-week high, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $6.80B in 2025, supported by an 80.2% gross margin and robust cash flow from operations of $2.59B. Analyst sentiment is mixed, with 42% buy ratings but a consensus price target of $158.64 below the current price.
Outlook remains positive due to cybersecurity demand and AI-driven growth, but high valuation ratios (P/E of 66.82) pose risks. Competition and execution challenges could pressure margins. Institutional interest is strong, with recent position increases noted in SEC filings. The stock's momentum depends on continued earnings outperformance and market share gains in data center security.
XBI trades at $150.23, down 0.44% on the day, with a bearish technical signal driven by moving averages and oscillators. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than broader healthcare funds.
The outlook is mixed: strong sector tailwinds from innovation and consolidation support growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst sentiment is neutral with 100% hold ratings, suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fortinet Inc
Fortinet is a cybersecurity vendor that sells products, support, and services to small and midsize businesses, enterprises, and government entities. Its products include unified threat management appliances, firewalls, network security, and its security platform, Security Fabric. Services revenue is primarily from FortiGuard security subscriptions and FortiCare technical support. At the end of 2021, products were 38% of revenue and services were 62% of sales. The California-based company sells products worldwide.
Read more on FTNT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
